- Home
- PDX vs EVMN Comparison
PDX vs EVMN Comparison
Compare PDX & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PDX | EVMN |
|---|---|---|
| Founded | 2019 | 2020 |
| Country | NY | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 904.4M | 892.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PDX | EVMN |
|---|---|---|
| Price | $20.07 | $27.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $44.17 |
| AVG Volume (30 Days) | 113.8K | ★ 955.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 4.95% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $89.43 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $18.47 | $13.89 |
| 52 Week High | $25.61 | $33.20 |
Technical Indicators
Market Signals| Indicator | PDX | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 51.13 | 52.24 |
| Support Level | $19.91 | $15.80 |
| Resistance Level | $20.36 | $33.20 |
| Average True Range (ATR) | 0.19 | 3.68 |
| MACD | -0.00 | -0.24 |
| Stochastic Oscillator | 49.06 | 55.89 |
Price Performance
Historical ComparisonAbout PDX PIMCO Dynamic Income Strategy Fund of Beneficial Interest
PIMCO Dynamic Income Strategy Fund is a non-diversified, limited-term, closed-end management investment company. It seeks current income as a primary objective and capital appreciation as a secondary objective. The fund makes investments using a dynamic asset allocation plan among multiple sectors in the public and private credit markets globally, including corporate debt, mortgage-related and other asset-backed instruments, government and sovereign debt, taxable municipal bonds, and other fixed, variable, and floating-rate income-producing securities of U.S. and foreign issuers, including emerging market issuers and real estate-related investments.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.